Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors inside the central nervous process, conolidine modulates alternate molecular targets. A Science Advances review found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://kirkx296hqf1.nizarblog.com/profile